---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-246740"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-09-19T23:59:59+00:00"
generated_at: "2026-06-23T08:47:12.725003+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller

## Summary
- Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.
- Jones previously CFO at LogicBio; 10+ years at Biogen in various finance roles including VP of R&D and BD finance.
- Compensation: $475k base salary, 45% target annual bonus, $1.875M stock option, $625k RSUs, $300k PSUs.
- Stock option vests: 25% on first anniversary, then monthly through year 4; RSUs vest equally over 3 years.
- Company highlights PYRUKYND commercial launch and five pivotal trials; Jones to lead financial strategy.

## SEC filing metadata
- accession: 0001193125-22-246740
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/0001193125-22-246740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/d367124d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-246740
- JSON: https://secwatch.observer/filing/0001193125-22-246740.json
- Plain text: https://secwatch.observer/filing/0001193125-22-246740.txt

## Key facts
- Executive change
  Cecilia Jones was appointed as Chief Financial Officer at AGIOS PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/0001193125-22-246740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.